Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding their holdings of Ordinary share American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The filing details an increase in ADR holdings for specific directors and connected persons resulting from the re-investment of dividends paid on January 5, 2012. The transactions occurred at a price of $46.165 per ADR. Specific increases include:
- Dr M M Slaoui: 412.646 ADRs
- Dr K Slaoui (Connected Person): 8.790 ADRs
- Mr W C Louv: 179.889 ADRs
- Dr D Pulman: 259.197 ADRs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory compliance notification regarding insider trading rules under Disclosure and Transparency Rules 3.1.4R(1)(a) and (c).
Investor Verification Points
- Verify the dividend reinvestment price of $46.165 per ADR against market data for January 5, 2012.
- Confirm the total ADR holdings of the listed directors post-transaction to assess concentration of ownership.
- Review the company's broader dividend policy and payout history for context on the reinvestment mechanism.